Colon cancer warning signal should never be ignored

Share This Post

According to the CDC, colorectal cancer is the third most common cancer diagnosed in the United States and the second leading cause of cancer death in the United States.

You might think this is a problem for the elderly, but more and more adults in their 20s and 30s are diagnosed with colorectal cancer .

Here are six symptoms you should not ignore:

  1. bleeding

The most common warning sign is rectal bleeding.When the toilet You may find toilet paper, toilet inside or feces in mixed with blood, blood may be bright red or deep maroon.

  1. Iron deficiency anemia

When the junction straight while bleeding colorectal tumors, the body will lead to loss of iron. People often are not conscious that they’re bleeding, but routine blood tests will discover anemia, red blood cells or healthy reduction.

  1. Abdominal pain

The tumor may cause blockage or tearing, causing cramps and other pain. The pain may be the intestinal barrier signs also may experience nausea, vomiting and abdominal distension.

4.Feces become narrow

Doctors call this a change in stool caliber. If your stool is often thinner than before, this may indicate a tumor in the colon. Pay attention to other changes in bowel habits, such as constipation.

5.Invalid defecation feeling

Feel themselves must discharge it, but when you try,but no stool. This may be caused by a tumor in the rectum.

  1. Unexplained weight loss

I feel like I have eaten enough, but colorectal cancer can change the way your body eats nutrients, preventing you from absorbing all the nutrients and causing weight loss.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy